Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD

This study is testing a combination of four drugs — daratumumab, bortezomib, cyclophosphamide, and dexamethasone — to treat a rare kidney disease called monoclonal immunoglobulin deposition disease (MIDD), where abnormal proteins produced by certain blood cells deposit in the kidneys and cause damage. **You may be eligible if...** - You have been diagnosed with MIDD and have not yet received treatment targeting the underlying plasma cell disease - Your general health is acceptable (ECOG 0, 1, or 2) - Your blood counts and liver function are within acceptable ranges - You understand the study and have signed informed consent **You may NOT be eligible if...** - You have previously received treatment for MIDD (other than a small amount of steroids) - You meet the criteria for active multiple myeloma or active lymphoplasmacytic lymphoma - You have another advanced cancer with widespread spread - You have an active serious infection that cannot be controlled - You have a severe autoimmune disease or immune deficiency - You have active hepatitis B, hepatitis C, HIV, or syphilis Talk to your doctor to see if this trial is right for you.